Tech Company Financing Transactions
Hinge Bio Funding Round
Point72 Ventures, InVivium Capital and Lightswitch Capital participated in a $30 million Series A funding round for Hinge Bio. The round was announced on 1/15/2025.
Transaction Overview
Company Name
Announced On
1/15/2025
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support entry of its lead product candidate, HB2198, into a Phase 1 clinical trial in patients living with Systemic Lupus Erythematosus ("Lupus") as well as development of additional therapeutics from its proprietary GEM-DIMER� platform to treat diseases with high unmet need.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Burlingame, CA Undisclosed
USA
Burlingame, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Hinge Bio, a Burlingame, CA-based biotechnology company.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Barry Selick
Browse more venture capital transactions:
Prev: 1/15/2025: Conceivable Life Sciences venture capital transaction
Next: 1/16/2025: MetAI venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records on this site come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs